TOKYO (Reuters) – Japan has approved GlaxoSmithKline (NYSE:GSK) and Vir Biotechnology (NASDAQ:VIR)’s Sotrovimab as an antibody treatment for coronavirus, Health Minister Norihisa Tamura said on Monday.
The antibody treatment is for mild to moderate COVID-19 cases which do not require oxygen supplementation, GSK said when it applied for fast-track approval this month.
Japan approves GSK’s Sotrovimab COVID-19 antibody treatment
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.